KOBIPC Analysis
Open 294.75
DayLow: 290.45
DayHigh: 295.1624
52 Week Low: 253.3
52 Week High: 346.85
50 Days Average: 274.9592
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
The Ichimoku Cloud
The Ichimoku Cloud is a technical analysis tool used to gauge market trends, momentum, and potential support/resistance levels in trading. It consists of five lines that create a "cloud" on a price chart, helping traders make decisions. Here's a simple breakdown:- Tenkan-Sen (Conversion Line): A short-term trend indicator, calculated as the average of the highest high and lowest low over the past 9 periods.
- Kijun-Sen (Base Line): A medium-term trend indicator, calculated as the average of the highest high and lowest low over the past 26 periods.
- Senkou Span A (Leading Span A): Forms one edge of the cloud, calculated as the average of the Tenkan-Sen and Kijun-Sen, plotted 26 periods ahead.
- Senkou Span B (Leading Span B): Forms the other edge of the cloud, calculated as the average of the highest high and lowest low over the past 52 periods, plotted 26 periods ahead.
- Chikou Span (Lagging Span): The current closing price plotted 26 periods behind, showing potential support/resistance.
- Price Above the Cloud: Indicates an uptrend.
- Price Below the Cloud: Indicates a downtrend.
- Price Inside the Cloud: Suggests consolidation or indecision.
- Cloud Thickness: A thicker cloud indicates stronger support/resistance, while a thinner cloud suggests weaker levels.